Related Experiment Videos
Before oral agents fail: the case for starting insulin early
1Service de Diabétologie/Endocrinologie, Hôpital Bichat Claude Bernard, Paris, France. michel.marre@bch.ap-hop-paris.fr
Summary
Early insulin initiation, combined with oral agents, improves type 2 diabetes management. This strategy enhances metabolic control and offers a smoother transition to insulin therapy, reducing complications.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes (T2D) is progressive, necessitating adaptable treatment strategies.
- Strict metabolic control is crucial to mitigate diabetic morbidity and mortality.
- Treatment typically escalates as beta-cell function declines, impacting oral agent efficacy.
Purpose of the Study:
- To evaluate the benefits of early insulin initiation in T2D management.
- To assess the role of combination therapy (insulin with oral hypoglycaemic agents) in improving glycaemic control.
- To explore the advantages of premixed insulin analogues in T2D treatment.
Main Methods:
- Review of treatment paradigms for Type 2 Diabetes.
- Analysis of the impact of beta-cell function on oral hypoglycaemic agent (OHA) efficacy.
- Evaluation of insulin therapy as a progression from OHA treatment.
Main Results:
- Insulin combined with OHAs significantly improves glycaemic control.
- Combination therapy offers a transitional phase ('bridge') to insulin-only treatment.
- Premixed insulin analogues with OHAs provide effective postprandial control and a convenient regimen.
Conclusions:
- Early initiation of insulin therapy in T2D is prudent for optimal metabolic control.
- Combination therapy with insulin and OHAs is effective and well-tolerated.
- Premixed insulin analogues offer a practical and effective option for combination therapy in T2D.